Last year's acquisition of Haleon's global NRT business (excluding the US) for over Rs 5,000 crore, has 'exceeded' ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

Indian pharmaceutical companies Sun Pharma, Lupin, and Dr Reddy's Laboratories are conducting recalls in the US due to ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Stocks including Kotak Mahindra Bank, RITES, IndusInd Bank, IDFC First Bank, Dr Reddy's Labs, CDSL, Bank of Baroda, SAIL and ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

DRL posted a 2 per cent YoY increase in PAT to Rs 1,417.8 crore for Q1 FY26, compared with Rs 1,392 crore in the year-ago ...

Dr. Reddy's Laboratories Ltd. closed 10.04% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).